This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Firms Expecting Clinical Trial Results

Company: Ariad Pharmaceuticals (ARIA - Get Report)

Drug/indication: Ridaforolimus for sarcoma

Estimated timing: Before year's end.

Recent stock performance: Closed Tuesday at $2.73, off its recent high of $4.25 reached in mid May.

The phase III "SUCCEED" study is designed to detect a 33% improvement in median progression-free survival between "rida" and placebo in patients with soft-tissue or bone sarcoma who were previously treated, successfully, with chemotherapy. Full enrollment in the study of 650 patients was reached in December 2009 and independent study monitors completed their last interim check in May, recommending the study proceed to a final analysis.

Ariad licensed worldwide commercial rights to rida to Merck (MRK). The two companies recently restructured the terms of the partnership.

2 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ARIA $9.05 -6.80%
BMRN $116.97 -2.75%
AZN $70.76 -1.43%
CORT $6.19 -2.06%
CYCC $0.93 -2.89%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs